Skip to main content
. Author manuscript; available in PMC: 2013 Nov 21.
Published in final edited form as: Clin Cancer Res. 2012 May 1;18(9):10.1158/1078-0432.CCR-11-3167. doi: 10.1158/1078-0432.CCR-11-3167

Figure 2.

Figure 2

PTEN-null cells exhibit sensitivity to saracatinib in a xenograft model. The (A) PTEN-null (−/−) and (B) wild-type (+/+) cell lines were injected in axenograft model to examine the antitumor effects of saracatinib in vivo. When tumor volumes reached approximately 200 mm3, mice were randomized and treated with saracatinib 50 mg/kg/d by oral gavage for 12 days. Tumor size was evaluated twice per week by caliper measurements by the formula: tumor volume = (length × width2) × 0.52. Treatment with saracatinib resulted in a significant decrease in growth in the PTEN-nul cell line (*, P < 0.05). C, evaluation of the activation of Src and Akt in PTEN wild-type and -null tumors. Baseline levels of p-Src and p-Akt were increased in the PTEN-null tumor when compared with wild-type.